DSIP (10mg) is a synthetic nonapeptide originally identified in studies examining naturally occurring brain peptides associated with sleep physiology. Known scientifically as delta sleep-inducing peptide, this small neuropeptide has been investigated for its effects on sleep-related physiology, neuroendocrine signaling, and stress-related biological processes.

Due to its compact structure and water-soluble characteristics, it is widely used in laboratory studies exploring neurochemical signaling and activity within the central nervous system.

Current DSIP research focuses on experimental models that examine sleep-related neurobiology, circadian physiology, and stress-related adaptation in controlled research environments.

DSIP (10mg) Key Features & Specs

• Subcategory: Brain, Cognitive & Nootropic Peptides
• Strength: 10 mg
• CAS: 62568-57-4
• Chemical Formula: C₃₅H₄₈N₁₀O₁₅
• Molecular Weight: 848.8 g/mol
• Peptide Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
• Synonyms: Emideltide, Delta sleep-inducing peptide

The DSIP sleep peptide is provided as a research-grade material for laboratory experiments investigating neural signaling and circadian physiology.

DSIP (10mg) Research Uses

DSIP has been studied in experimental systems related to sleep physiology, neuroendocrine activity, and stress regulation. Because it was first linked to sleep-associated brain activity, many laboratory investigations focus on how the peptide interacts with sleep-wake-related cycles and hormonal rhythms.

Common areas of investigation include:

• Sleep Physiology: Studies evaluating slow-wave sleep (SWS) patterns and electroencephalogram (EEG) changes in animal models.
• Neuroendocrine Signaling: Experiments examining hormone responses such as growth hormone, cortisol, and vasopressin during sleep cycles.
• Stress and Adaptation Models: Laboratory work analyzing how peptide signaling may influence physiological responses to environmental or metabolic stress.
• Neuroprotection and Cellular Metabolism: Research exploring antioxidant-enzyme-activity-related readouts, mitochondrial responses, and neuronal-survival-related markers.

Across these fields, DSIP is used as a biochemical tool to explore how small endogenous peptides may influence sleep-related physiology and neural-regulatory-related systems.

DSIP (10mg) Insights & Observed Findings

Experimental literature reports several observations regarding DSIP under controlled laboratory conditions.

• Animal Studies: In rodent models examining cerebral ischemia, DSIP administered intranasally at 120 µg/kg before and after induced ischemia was associated with changes in motor-coordination-related readouts and behavioral performance compared with untreated groups, although differences in brain lesion size were not always significant.
• Human Studies: Short-term administration in volunteers was reported to be well tolerated, though sleep-related outcomes varied across studies. Clinical experiments evaluating DSIP-like immunoreactivity and its daily rhythm revealed a clear diurnal pattern that correlated with fluctuations in body temperature.

These findings support continued DSIP research while highlighting the complexity of the peptide’s physiological role.

DSIP (10mg) Handling & Storage

• Store DSIP (10mg) in its lyophilized form at –20 °C or below in the original sealed vial. The vial should be protected from light and moisture before use.
• Allow the vial to reach room temperature prior to opening to help prevent condensation.
• Reconstitution should be carried out with sterile, particle-free aqueous buffer using an aseptic technique appropriate for peptide handling in laboratory environments.
• Reconstituted peptide solutions are typically stored under refrigeration at 2–8 °C for use in the same experimental session or as specified by the investigator, and protected from light.
• Disposal of unused material should follow institutional laboratory safety procedures and regulatory guidelines for research chemicals.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences. 1977;74(3):1282-1286. doi:10.1073/pnas.74.3.1282
2. Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proceedings of the National Academy of Sciences. 1988;85(10):3653-3656. doi:10.1073/pnas.85.10.3653
3. Friedman TC, Garcia-Borreguero D, Hardwick D, et al. Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. J Clin Endocrinol Metab. 1994;78(5):1085-1089. doi:10.1210/jcem.78.5.8175965
4. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. doi:10.1159/000117964
5. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. doi:10.1159/000118919